Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

gram (304) and two Ambulatory Blood Pressure Monitoring (ABPM) studies (111 and 112), which showed naproxcinod's favorable 24-hour blood pressure profile. - Signature of two commercial supply agreements for naproxcinod with world leading manufacturing companies: DSM for the production of active pharmaceutical ingredient (API) and Capsugel for the production of naproxcinod capsules. - Further progress in the collaboration with Merck & Co., Inc., following the initiation of a series of phase 1b studies in mild to moderate hypertensive volunteers, which have the aim of selecting the most appropriate compound to advance into phase 2. - Two phase 2 studies for PF-03187207 in glaucoma patients conducted by Pfizer Inc demonstrated an improvement over Xalatan(R) 0.005%, in terms of intraocular pressure lowering, but did not reach statistical significance on the primary endpoint.

Eric Castaldi, Chief Financial Officer of NicOx, commented: "As planned, we successfully completed the phase 3 clinical program for naproxcinod in 2008. We believe that the attractive profile of naproxcinod achieved in the phase 3 program should ensure our compound's future commercial success. Our balance sheet has enabled us to continue to expand the pre-commercialization activities for naproxcinod in parallel with the ongoing partnering discussions. We project cash burn will substantially decline throughout 2009, following the completion of the phase 3 program, and we currently believe we have sufficient cash to finance the activities of the Company until the end of 2010. This projection does not include the possible upfront and milestone payments we expect from a potential commercialization agreement for naproxcinod."

Financial summary of 2008

Revenues for the full year 2008 were EUR3.4 million, compared to EUR20.6 million in 2007. These
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... DIEGO, June 8 , , WHO: ... and panelists discussing life sciences and the business relationships between California ... , CALAsia is an international 2-day forum that will bring ... Asia Pacific region to identify, explore, and further trans-Pacific business endeavors. ...
... International, a leader in enabling and accelerating the global ... today announced a strategic drug co-development partnership with the ... of therapeutic areas and represents one of the first ... company and a Chinese university. , , HUYA ...
... June 8 CSL Limited (ASX: CSL) and Talecris Biotherapeutics, ... their merger agreement, announced on August 12, 2008, under which ... , , Dr. Brian McNamee, CEO and Managing Director ... Federal Trade Commission (FTC) resolved to block the transaction. ...
Cached Biology Technology:BIOCOM's Inaugural CALAsia Forum 'Bridging the Pacific' 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 3CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency is insourcing ... prevent counterfeit microcircuits from entering into its supply chain. ... microcircuit anti-counterfeit initiative dubbed DNA marking. The capability will ... reliability throughout the supply chain. The new quality control ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... metabolic symptoms of 11 patients with a rare but ... (MSUD), according to a study by researchers from Children's ... , All patients from the study (ranging in age ... function, according to the researchers. Amino acid levels in ...
... A major conservation effort, led by Dr Brendan Godley ... to help protect endangered leatherback turtles which nest in ... the animals' last global stronghold, as pacific populations dwindle ... track the animals, will uncover their migratory secrets and ...
... Research Consortium scientists from The Walter and Eliza Hall ... stem cell that drives the formation of all breast ... how normal breast tissue develops. The identification of the ... about how breast cancer develops and how rogue cells ...
Cached Biology News:Pennsylvania researchers find liver transplants provide metabolic cure for rare genetic disease 2Scientist warns of threat to last stronghold of endangered turtle 2Faults in newly discovered breast stem cells may lead to tumours 2
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... acquisition, analysis and experiment control software. ... with on-line and off-line analysis. powerful ... script language allowing the user to ... requirements. Applications range from basic data ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
Biology Products: